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Tetranectin, a plasminogen-binding protein with a C-type lectin domain, is found in both serum and the extracellular
matrix. In the present study we report that tetranectin is closely associated with myogenesis during embryonic
development, skeletal muscle regeneration, and muscle cell differentiation in vitro. We find that tetranectin expression
coincides with muscle differentiation and maturation in the second half of gestation and further that tetranectin is
enriched at the myotendinous and myofascial junctions. The tetranectin immunostaining declines after birth and no
immunostaining is observed in normal adult muscle. However, during skeletal muscle regeneration induced by the
intramuscular injection of the myotoxic anesthetic Marcaine, myoblasts, myotubes, and the stumps of damaged
myofibers exhibit intense tetranectin immunostaining. Tetranectin is also present in regenerating muscle cells in
dystrophic mdx mice. Murine C2C12 myogenic cells and pluripotent embryonic stem cells can undergo muscle cell
differentiation in vitro. Tetranectin is not expressed in the undifferentiated myogenic cells, but during the progression
of muscle differentiation, tetranectin mRNA is induced, and both cytoplasmic and cell surface tetranectin immuno-
staining become apparent. Finally, we demonstrate that while tetranectin mRNA is translated to a similar degree in
developing limbs and lung, the protein does not seem to be tissue associated in the lung as it is in the limbs. This
indicates that in some tissues, such as the limbs, tetranectin may function locally, whereas in other tissues, such as
the lung, tetranectin production may be destined for body fluids. In summary, these results suggest that tetranectin is
a matricellular protein and plays a role in myogenesis. © 1998 Academic Press
INTRODUCTION
The extracellular matrix (ECM) has important structural
and functional roles in forming and maintaining tissue
architecture as well as in promoting cell adhesion and cell
survival (Adams and Watt, 1993; Ruoslahti and O¨brink,
1996; Meredith and Schwartz, 1997). Major structural com-
ponents of the ECM include collagens, proteoglycans, and
laminins (Engvall and Wewer, 1996; Iozzo and Murdoch,
1996; Mundlos and Olsen, 1997). Matricellular proteins
constitute a diverse group of ECM-associated proteins that
modulate cell–matrix interactions but do not contribute
significantly to ECM structure (Sage and Bornstein, 1991;
Bornstein, 1995). The best-studied examples are SPARC,
thrombospondin, and tenascin, but other macromolecules
may have similar properties, such as tetranectin as pro-
posed in the present study.
Tetranectin was originally purified from serum on the
basis of its plasminogen kringle 4-binding properties (Clem-
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mensen et al., 1986). Tetranectin is composed of three
identical, noncovalently linked subunits each of 181 amino
acids (Clemmensen et al., 1986; Fuhlendorff et al., 1987;
Berglund and Petersen, 1992; Wewer and Albrechtsen, 1992;
Nielsen et al., 1997). The polypeptide consists of a short
a-helical segment at the amino terminus that is involved in
trimerization, followed by a C-type lectin domain. The
C-type lectin domain is an approximately 120-amino-acid
sequence that binds to polysaccharides in a calcium-
dependent manner and is found in a number of secreted and
cell surface proteins (Drickamer, 1993). Consistent with the
presence of a C-type lectin domain, tetranectin has been
shown to bind calcium ions (Clemmensen et al., 1986). The
carbohydrate binding properties of tetranectin have not
been determined, although it possesses the sequence QPD
found in galactose-binding lectins (Drickamer, 1993). Tet-
ranectin also binds to heparin (Clemmensen et al., 1986),
heparan and chondroitin sulfate (Clemmensen, 1989), fibrin
(Kluft et al., 1989b), and apolipoprotein(a) (Kluft et al.,
1989a). Tetranectin is present in serum at a concentration
of 15 6 2 mg/liter (Jensen and Clemmensen, 1988), but the
cellular source(s) is not known. By Northern blot analysis,
tetranectin mRNA has been found in various adult tissues,
including lung, spleen, skeletal muscle, and heart (Wewer
and Albrechtsen, 1992; Berglund and Petersen, 1992; Ibaraki
et al., 1995; Sørensen et al., 1995).
Tetranectin is present in some ECM. While low levels of
tetranectin are found in normal adult tissues, it is accumu-
lated in the stroma of various carcinomas (Christensen and
Clemmensen, 1991; Wewer and Albrechtsen, 1992; Høgdall
et al., 1993; DeVries et al., 1996), a distribution pattern
similar to that of SPARC, thrombospondin, and tenascin
(Wewer et al., 1988; Chiquet-Ehrismann, 1993; Roberts,
1993; Porter et al., 1995). SPARC, thrombospondin, and
tenascin are also expressed during morphogenetic pro-
cesses, including bone formation (Sage and Bornstein, 1991;
Gehron Robey et al., 1992), and recent studies indicate that
tetranectin may be involved in osteogenesis (Wewer et al.,
1994; Iba et al., 1995). In developing bone, tetranectin
immunoreactivity is found in the newly formed woven
bone, and tetranectin mRNA is induced at the mineraliza-
tion stage in both bovine and human in vitro osteogenic
cultures. In human osteogenic cell cultures, the increase in
tetranectin mRNA during differentiation could be inhibited
by TGF-b (Iba et al., 1995). Evidence for a more direct role
for tetranectin in osteogenesis was obtained from studies in
which tetranectin-transfected PC12 cells injected into nude
mice produced tumors containing a significant increase in
bone material (Wewer et al., 1994). These studies indicate
that tetranectin is one of several ECM-associated proteins
with critical roles in modifying cell behavior.
In the present study we report that tetranectin is associ-
ated with another mesenchymal differentiation pathway,
skeletal muscle myogenesis. We demonstrate that tetranec-
tin mRNA and protein are markers of myogenesis during
embryonic development, muscle regeneration, and muscle
differentiation in vitro. Furthermore, tetranectin immuno-
staining is enriched at the myotendinous junction, suggest-
ing a role in the formation and/or stabilization of this
adhesion structure that is specialized for force transmission
from muscle to tendon. This distinct tissue distribution
indicates that tetranectin may function during muscle cell
differentiation and maturation.
MATERIALS AND METHODS
Animals. C57BL/6J and NMRI mouse embryos of different ages
(the day of the vaginal plug was considered day 0.5), newborn, and
1- and 2-month-old mice were examined. SJL/J mice were used to
study muscle regeneration because this strain has been found to be
superior in muscle regeneration after injury (Mitchell et al., 1992).
The tibialis anterior muscle was surgically exposed and 50 ml of 5
mg/ml Marcaine (bupivacaine, obtained from Astra, Denmark) was
injected intramuscularly through a 25-gauge needle (Benoit and
Belt, 1970). The contralateral muscle was injected with the same
volume of PBS as a control. Muscle tissue specimens from
dystrophin-deficient mdx mice (on a C57BL/6J background) that
exhibit a continuous pattern of regeneration throughout their
lifespan were also investigated. Mice were obtained from Bomholt-
gaard, Denmark, except for the mdx colony that was obtained from
Jackson Laboratory and maintained at Burnham Institute (La Jolla,
CA). All mouse experiments were approved by the Animal Experi-
ments Inspectorate, Copenhagen. The terminology of Hauschka
(1994) for different types of muscle cells is used.
Cell culture. The COS-7 and the C2C12 mouse cell lines were
obtained from ATCC (Rockville, MD) and were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) with Glutamax I and
4500 mg/ml glucose, 50 U/ml penicillin and 50 mg/ml streptomy-
cin, and 10% fetal bovine serum (Gibco-BRL) at 37°C in 5% CO2 in
air. Myogenic differentiation of the C2C12 cells was induced at
confluence by replacing the growth medium with DMEM contain-
ing 2% horse serum (Gibco-BRL) as described (Vachon et al., 1996).
The pluripotent embryonic stem (ES) cell line E14.1 (ATCC) was
cultured on mitomycin C-treated mouse embryonic fibroblasts
(feeder cells) from neomycin-resistant CBA/C8 mice in ES culture
medium (DMEM, 15% ES cell-qualified fetal calf serum, 2.4 mM
L-glutamine, 0.1 mM 2-mercaptoethanol, 0.1 mM nonessential
amino acids, 100 U/ml penicillin G, 100 mg/ml streptomycin
sulfate, 0.25 mg/ml amphotericin B, and 1000 U/ml human leuke-
mia inhibiting factor) and induced to differentiate as described (Liu
et al., 1997; Kuang et al., 1998a). Briefly, embryoid bodies were first
allowed to form in 20-ml hanging-drop cultures for 4.5 days and
then plated onto gelatin-coated 13-mm glass coverslips and cul-
tured for 30 days before immunostaining analysis.
RNA extraction, Northern blotting, and RT-PCR. Total RNA
was extracted from whole mouse embryos, extraembryonic tissue,
organs of newborn mice, and the C2C12 cells by the guanidine
isothiocyanate method (Chomczynski and Sacchi, 1987) or with
TRIzol reagent (Gibco-BRL). For Northern analysis, 20 mg of total
RNA per lane was denatured with formamide/formaldehyde and
separated on 1.2% agarose/formaldehyde gels (Sambrook et al.,
1989). RNA was capillary blotted onto Hybond N1 nylon mem-
branes (Amersham) and fixed by UV irradiation. The blots were
hybridized to the insert of the full-length mouse tetranectin cDNA
clone pM-tna (Ibaraki et al., 1995), labeled with [a-32P]dCTP by the
random primer method using a kit from Amersham. Hybridization
was performed for 1 h at 68°C in QuikHyb hybridization solution
(Stratagene) according to the manufacturer’s protocol. After wash-
ing three times with 23 SSC/0.1% SDS at 65°C and twice with
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0.23 SSC/0.1% SDS at 65°C, the blots were exposed to Kodak
X-OMAT AR film at 280°C with intensifying screens.
For RT-PCR, 5 mg of total RNA was used to synthesize cDNA using
MMLV reverse transcriptase as recommended by the manufacturer
(Stratagene). Aliquots of cDNA equivalent to 125 ng of total RNA
were amplified with the forward primer 59-GCAGTATGGGATT-
TTGGG (nt 77–95) and the reverse primer 59-GGCACTTCAAGTT-
CACCTTGGTG (nt 303–325). After an initial denaturation at 95°C
for 40 s, 35 cycles of denaturation at 94°C for 40 s, annealing at 60°C
for 40 s, and extension at 72°C for 60 s were carried out. The reaction
products were separated on agarose gels, blotted onto Hybond N1
nylon membranes, and hybridized overnight at 42°C in 50 % form-
amide (Sambrook et al., 1989) to a 0.2-kb EcoRI–SacI fragment from
the 59 end of the pM-tna to assay for the presence of the 249-bp
tetranectin-specific amplification product. To confirm the identity of
the PCR product, the amplified DNA fragment was cloned into the
vector pCR 2.1 using the TA cloning kit (InVitrogen) and sequenced
with vector primers using the Vistra DNA Sequencer 725 (Amersham
Corp.). As a control the same cDNA samples were amplified using
primers for the mouse GAPDH cDNA sequence: 59-AAGGTCATC-
CCAGAGCTGAACG (nt 695–716 of GenBank M32599) and 59-
TGTCATACCAGGAAATGAGC (complementary to nt 967–986),
using the same conditions as above except that the annealing tem-
perature was 55°C.
Expression constructs for immunization and transfection.
Polyclonal and monoclonal antibodies were prepared to a mouse
tetranectin His-tagged fusion protein produced in Escherichia coli.
A 0.56-kb cDNA fragment (nt 143–690) that encodes the mature
tetranectin polypeptide was constructed by PCR, using the follow-
ing primers: sense, 59-GAGGATCCAGAGTCACCCACTCCCA
(nt 143–160 plus BamHI linker); antisense, 59-CAACCCGGGC-
TACACAATGGCAAAC (nt 675–690 plus SmaI linker). PCR was
performed using Pfu polymerase (Stratagene) and the full-length
mouse cDNA clone pM-tna as a template. The product was
digested with BamHI and SmaI, ligated to BamHI- and SmaI-cut
pQE31 His-tagged expression vector (Qiagen), giving plasmid
p1000, and transformed into E. coli strain DH5a (Gibco-BRL)
carrying the repressor plasmid pREP4 (Qiagen). Recombinant tet-
ranectin produced in E. coli was then purified by immobilized
metal affinity chromatography (Gilpin et al., 1998).
To prepare a plasmid for expression of full-length mouse tet-
ranectin in COS-7 cells (ATCC CRL 1651), a 0.63-kb PCR fragment
containing the entire open reading frame and the stop codon (nt
82–690) was generated using the same antisense primer as above
and the sense primer 59-AAGGTACCATGGGATTTTGGGGCA
(nt 82–97 plus a KpnI linker). The product was digested with KpnI
and SmaI and then ligated to KpnI- and EcoRV-cut pcDNA3
(InVitrogen) to give plasmid p1036, which directs expression of
tetranectin under the control of the CMV promoter.
Polyclonal antibodies to tetranectin. Lewis rats (Møllegaar-
den, Denmark) and rabbits (Statens Seruminstitut, Copenhagen)
were immunized and boosted several times at monthly intervals
with recombinant mouse tetranectin derived from expression con-
struct p1000 (see above) emulsified in complete and incomplete
Freund’s adjuvant. Ten or 11 days after each boost the animals were
bled. Sera from two rabbits, rb 35HA and rb 107, were used in the
present study. Polyclonal antiserum to human tetranectin was
purchased from DAKO a/s (Code A371). We tested the polyclonal
antibodies for cross-reactivity to avian tetranectin by Western
blotting of chicken serum and found that they do not cross-react
(not shown).
Monoclonal antibodies to tetranectin. Rats were immunized
and boosted 10 times as described above. A final boost was given
intraperitoneally and 3 days later hybridomas were prepared by
fusing spleen cells from the rat with the nonsecreting mouse
myeloma P3 3 63Ag8.653 (ATCC TIB 18) as described (Gilpin et
al., 1998). Supernatants of the resulting hybridomas were screened
for (a) their immunostaining of COS-7 cells transiently transfected
with the full-length cDNA construct p1036 and (b) their reactivity
with serum tetranectin in Western blotting. The COS-7 cells were
electroporated and immunostained as previously described (Gilpin
et al., 1998). The isotype of the rat 1B11 hybridoma was IgG1 kappa
as determined by Ouchterlony immunodiffusion using a series of
anti-rat immunoglobulins purchased from Serotec and by the
IsoStrip kit from Boehringer-Mannheim. The hybridoma was
cloned by limited dilution and retested for reactivity and specific-
ity. Hybridomas were grown in DMEM with Glutamax I and 4500
mg/ml glucose, 1 mM sodium pyruvate, 10 mM Hepes, 50 U/ml
penicillin and 50 mg/ml streptomycin, and 20% fetal bovine serum
(Gibco-BRL) at 37°C in 10% CO2. Ascites fluid was generated in
nu/nu NMRI mice.
Other antibodies. Mouse mAb to the skeletal muscle marker
protein myogenin (Novocastra, NCL-Myf4) that react with both
human and mouse myogenin and polyclonal rabbit anti-skeletal
myosin antiserum (Sigma M-7523) were used.
ELISA and immunoblotting. To test the specificity and the
titer of the antibodies, ELISA plates (Nunc) were coated with 5–25
mg/ml of purified recombinant tetranectin and reacted with serial
dilutions of antibodies, followed by secondary antibodies and
staining according to established methods (Engvall, 1989).
For immunoblotting, mouse and human sera, or frozen sections
of mouse embryos, were extracted in boiling SDS–PAGE sample
buffer and fractionated by SDS–PAGE using 4–20% gradient gels
(Novex). Markers for molecular weight determination were See-
Blue prestained standards from Novex. Samples separated by SDS–
PAGE were transferred to BA 85 nitrocellulose (Schleicher and
Schuell). Nitrocellulose strips were incubated in 5% nonfat dry
milk in 0.05 M Tris–HCl, pH 7.4, 0.15 M NaCl, and 0.2% antifoam
B for 2 3 20 min at room temperature. Primary antibodies were
diluted 1:100–1:1000 in the same nonfat dry milk solution and
incubated with the nitrocellulose strips overnight at 4°C with
gentle shaking. Alkaline phosphatase-conjugated affinity-purified
swine immunoglobulins to rabbit (D0306, DAKO) or rat immuno-
globulins (5383A, Promega) were diluted 1:100 in the milk solution
and incubated for 1 h. After washing, the immunoreactivity was
visualized with nitrotetrazolium blue and 5-bromo-4-chloro-3-
indolylphosphate.
Immunostaining. Tissue specimens were fixed in formalin at
room temperature in cold Carnoy’s fixative or in 99 % ethanol/
glacial acetic acid (99:1 v/v) overnight at 4°C and embedded in
paraffin. Some embryos were snap frozen in liquid nitrogen and
stored at 280°C until use. Immunostaining for tetranectin was
performed essentially as described (Wewer et al., 1994). Briefly,
paraffin or frozen sections were exposed to the antibodies (1:100–
1:1000 dilution) and incubated for 24 h at 4°C in a humidified
chamber. After rinsing, the sections were incubated with secondary
antibodies, washed, and examined under a Zeiss LSM-10 laser-scan
microscope. For controls the specific antibodies were replaced with
irrelevant mouse monoclonal antibodies of the same isotype or
with normal mouse, rat, or rabbit serum.
Analysis of the translational activity of tetranectin mRNA
using isolated polysomes and slot-blot analysis. Frozen lungs
and limbs from newborn mice (;0.4 g) were pulverized with a
mortar and lysed in 500 ml of 20 mM Tris–HCl, pH 8.5; 1.5 mM
MgCl2; 140 mM KCl; 0.5 mM DTT; 0.5% NP-40; 1000 units/ml
RNasin (Promega); and 0.1 mM cycloheximide. The lysate was
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centrifuged at 10,000g for 10 min. The postmitochondrial superna-
tant was applied to a linear 20–47% sucrose gradient in 20 mM
Tris–HCl, pH 8.0; 140 mM KCl, supplemented with either 5 mM
MgCl2 or 10 mM EDTA to isolate polysomes or ribonucleoproteins
particles, respectively (Nielsen et al., 1990, 1995). Centrifugation
was carried out at 40,000 rpm for 2 h and 15 min in a Beckmann
SW41 rotor. Sucrose gradient fractions of 1 ml were collected with
concomitant measurement of the absorbance at 260 nm, the
fractions were extracted with phenol/chloroform, and the RNA
was recovered by ethanol precipitation. The distribution of tet-
ranectin mRNA in the fractions was analyzed by slot-blot hybrid-
ization (Nielsen et al., 1995). Filters were hybridized as described
above, and final washes were performed at 65°C in 0.23 SSC with
0.1% SDS. Hybridization signals were quantified with a BAS 2000
bioimager (Fuji).
RESULTS
Late onset of tetranectin mRNA expression during
mouse embryogenesis. Tetranectin mRNA was detected
at day 14.5 in whole mouse embryos by Southern blot
hybridization of RT-PCR products and at day 16.5 on
Northern blots, indicating that the amount of tetranectin
mRNA increased between days 14.5 and 16.5. From embry-
onic day 16.5 and until birth, tetranectin mRNA was
abundant (Figs. 1A and 1B). In placenta and extraembryonic
membranes, tetranectin mRNA was detected slightly ear-
lier, at day 12.5 by Southern blot hybridization of RT-PCR
products (Fig. 1C). In newborn mice tetranectin mRNA was
present in several tissues, most prominently in the limbs
and lung (Fig. 1D).
Characterization of tetranectin antibodies. To analyze
the temporal and spatial localization pattern of tetranectin
protein, we produced and characterized new polyclonal and
monoclonal antibodies to mouse tetranectin: rat (R10) and
rabbit polyclonal (rb35HA, rb107) antisera and a rat mAb
(1B11). These antibodies immunostained COS-7 cells tran-
siently transfected with a full-length tetranectin cDNA
expression construct, but not cells transfected with a con-
trol vector with no insert (not shown). In Western blotting
(Fig. 2A) the rat (lane 1), the rabbit polyclonal antisera, and
the 1B11 mAb (lane 2) recognized an ;25-kDa band in
mouse serum under reducing conditions. Similarly, an
;25-kDa band was observed in tissue extracts of 18-day
mouse embryos with the 1B11 mAb (lane 4). The mouse
tetranectin band in serum and embryo extracts comigrated
with human serum tetranectin (lane 5). The specificity and
titer of the antibodies were shown by ELISA using purified
recombinant tetranectin as the antigen (Figs. 2B and 2C).
We then used the antibodies to examine the distribution of
tetranectin on fixed, paraffin sections and frozen sections of
whole mouse embryos from day 10.5 of gestation and
onward.
Tetranectin is associated with myogenesis in mouse
development. In confirmation of previous results (Wewer
et al., 1994), we found that tetranectin is present during
osteogenesis and is localized in the newly formed woven
bone in the developing mouse embryo (not shown). In
addition to bone, the major site of tetranectin immuno-
staining during embryogenesis was the developing muscle
cells. The results are summarized in Table 1 and shown in
Figs. 3 and 4. The earliest detection of tetranectin immu-
noreactivity was in myoblasts and myotubes on day 12.5,
demonstrated in the myotome in Figs. 3A and 3B, in the
developing extrinsic ocular muscles in Figs. 3C and 3D, and
in the developing limb in Figs. 3E and 3F. At this stage the
myoblasts acquire a spindle-shaped morphology and begin
the formation of myotubes (Lyons and Buckingham, 1992).
By day 13–14 as the process of myotube formation and
maturation of myofibers occurs, prominent tetranectin im-
munostaining was present in most muscles of the trunk,
the limbs, and the head. As further maturation of muscle
takes place from day 15 and until birth, intense tetranectin
immunostaining was present in most muscle cells (Figs. 4A
and 4B). The appearance of tetranectin immunoreactivity in
the limb musculature was slightly delayed compared to
that of the trunk, consistent with the known developmen-
tal pattern. The intensity of the immunostaining declined
after birth and was negligible after 1 month (not shown).
The immunostaining of developing muscle cells was some-
what heterogeneous, probably reflecting the asynchronous
maturation of different muscles. A similar, but less intense,
FIG. 1. Expression of tetranectin mRNA during mouse embryo-
genesis and in newborn mice. (A) Southern blot analysis of RT-PCR
products amplified from total RNA from day 12.5 to day 19.5
mouse embryos and from newborn mouse limbs (NB). (B) Northern
blot analysis of total RNA isolated from whole mouse embryos
(days 12.5 to 19.5) and from newborn mouse limbs (NB). (C) The
upper panel shows Southern blot analysis of RT-PCR products
amplified from total RNA from day 12.5 and day 15.5 placenta and
extraembryonic membranes. The lower panel shows RT-PCR con-
trol with the 292-bp GADPH amplification product examined in
parallel, lanes 1–4, and visualized by ethidium bromide staining.
(D) Northern blot analysis of total RNA isolated from various
organs of newborn mice. The blots were hybridized to 32P-labeled
mouse tetranectin cDNA probes to detect the 249-bp tetranectin-
specific RT-PCR product and the l-kb tetranectin mRNA on
Southern and Northern blots, respectively.
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immunostaining pattern was obtained using polyclonal
antibodies to human tetranectin (not shown). Tetranectin
could be demonstrated in extracts of mouse embryos by
immunoblotting (Fig. 2A, lane 4), confirming the presence
of authentic tetranectin polypeptide.
Development of embryonic muscle in vivo involves the
formation of specialized junctions, such as the myotendi-
nous junctions at the ends of growing myofibers (Tidball,
1994) and the myofascial junctions at the interface between
muscle cells and the epimysium or fascia, the connective
tissue surrounding individual muscles (Ja¨rvinen et al.,
1992). Intense immunostaining of the myotendinous junc-
tion was obtained with anti-tetranectin antibodies, show-
ing that tetranectin is particularly enriched at these cell–
matrix junctional sites (Figs. 4C and 4D). The earliest that
tetranectin could be detected at those sites by immuno-
staining was at day 12.5 of gestation. Notably, the immu-
nostaining of the myotendinous junctions persisted after
birth and was present in neonates and in 1-month-old pups
and then ceased. In addition, the myofascial junctions were
immunoreactive after birth and the immunostaining ap-
peared to be localized extracellularly, at the border between
the muscle cells and connective tissue (Fig. 5).
Expression of tetranectin is stimulated in muscle regen-
eration after muscle injury and in mdx mice. Satellite
cells function as myogenic stem cells of the postnatal
skeletal muscle. Following muscle injury, satellite cells are
activated, proliferate, and differentiate into myotubes and
finally bridge the gap between the two stumps (Bischoff,
1994; Engel and Banker, 1994). As an experimental model
for muscle regeneration, mice were injected intramuscu-
larly with Marcaine, a local anesthetic known to induce
massive myonecrosis followed by rapid muscle regenera-
tion (Benoit and Belt, 1970). We investigated the distribu-
tion pattern of tetranectin 1, 3, 5, and 7 days after the
injection. One day after the injection, muscle fiber degen-
eration, necrosis, and infiltration with inflammatory cells
were present but no tetranectin immunostaining was ob-
served (not shown). At day 3 after the injection, tetranectin
immunostaining accumulated at the stumps of damaged
myofibers (Figs. 6A and 6B). Myogenin-positive myoblasts
exhibited a distinct tetranectin immunostaining (Fig. 6C).
Some myotubes and myofibers with centrally located nu-
clei likewise exhibited tetranectin immunoreactivity (not
shown). When the regeneration process was almost com-
plete 7 days after the injection, no tetranectin immuno-
staining was seen.
A variety of animal models for human muscular dys-
trophies serve as important tools not only for studying
the molecular mechanism of the disease (reviewed by
Nonaka, 1998), but also for developing novel rationales
for therapy (Vilquin et al., 1995; Tinsley et al., 1996;
Deconinck et al., 1997; Kuang et al., 1998b). We investi-
gated the distribution of tetranectin in mdx mice, a
TABLE 1





Body Limbs Body Limbs
E10.5–E11.5 2 2 2 2
E12.5 1 2 11 1
E13.5–E16.5 11 1 111 111
E17.5–E18.5 11 1 111 1
Newborn (1) (1) 1 1
One month old 2 2 1 1
Note. Tetranectin immunoreactivity in developing mouse
muscle is expressed as 111, strong, 11, moderate; 1, weak; (1),
very weak; and 2, undetectable. E is embryonic age in days.
FIG. 2. Characterization of monoclonal antibodies and demon-
stration of tetranectin in mouse embryo tissue by Western blotting.
Recombinant tetranectin produced in E. coli was used as an
immunogen to raise antibodies to mouse tetranectin. (A) In West-
ern blotting these reagents detected an ;25-kDa band in normal
mouse serum: lane 1, rat antiserum R10 (1:200); lane 2, mAb 1B11
(1:50); lane 3, normal rabbit serum. Note that in extracts of day 18.5
of gestation whole mouse embryos a similar-sized band was recog-
nized with the monoclonal antibody 1B11 (lane 4), demonstrating
that the tetranectin polypeptide was apparently abundant at this
time of gestation. As a control human serum (lane 5) was reacted
with a commercially available anti-human tetranectin antiserum
(1:300). (B) The His-tagged recombinant tetranectin was purified by
metal affinity chromatography and analyzed by SDS–PAGE. Lane
1, tetranectin; lane 2, molecular mass markers. (C) The purified
recombinant tetranectin was used in ELISA to confirm the speci-
ficity and titer of the antibodies. The dilution of mAb 1B11 (n),
antiserum rb 35H (), and normal serum (F) is shown together with
the absorbance at 495 nm. The data are expressed as means 6 SD.
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model for Duchenne muscular dystrophy. The skeletal
muscles of mdx mice go through rounds of muscle fiber
necrosis and an active regeneration that to a large extent
appear to compensate for muscle fiber loss. We found that
these regenerating muscle cells exhibit positive tetranec-
tin immunostaining. The pattern of tetranectin immuno-
reactivity is similar to that described for experimentally
induced regeneration; myoblasts and myotubes are
strongly positive (Fig. 7).
Tetranectin is a marker for myogenic differentiation of
C2C12 and ES cells in vitro. To determine whether tet-
ranectin is also expressed by cells undergoing myogenesis
in vitro, RT-PCR was used to compare the levels of tet-
ranectin mRNA in cultures of myogenic mouse C2C12
cells and in cultures induced to undergo muscle cell differ-
entiation by replacing the growth medium with DMEM
containing 2% horse serum (Figs. 8A and 8B). No tetranec-
tin mRNA could be detected when the cells were kept in
FIG. 4. Localization of tetranectin in developing muscle and myotendinous junctions (E15.5–E17.5). Mouse embryos of various
developmental ages were fixed in cold 96% ethanol/acetic acid (99:1 v/v), embedded in paraffin, and analyzed for the presence of tetranectin
immunoreactivity. Intense immunostaining using the rb 35 HA antiserum to mouse tetranectin was present intracellularly in muscle cells
at day 16.5 of gestation shown in A and using the rat R10 antiserum at 15.5 days of gestation shown in B. Accumulation of tetranectin was
observed at the myotendinous junctions at 17.5 days of gestation shown in C and larger magnification in D, using mAb 1B11. The
antibodies were used at a dilution of 1:100. Note that the surrounding stroma and cartilage were not immunoreactive. Sections were
counterstained with hematoxylin. Scale bars are 20 mm in A and B, 140 mm in C, and 40 mm in D.
FIG. 3. Localization of tetranectin in developing muscle (E12.5–E14.5). Mouse embryos of various developmental ages were fixed in cold
96% ethanol/acetic acid (99:1 v/v), embedded in paraffin, and analyzed for the presence of tetranectin immunoreactivity. (A) Cross-section
of a mouse embryo at day 12.5 of gestation at the caudal part of the medulla oblongata. Positive tetranectin immunostaining of the
myotome-derived premuscle muscle mass is seen, shown in larger magnification in B. In C, positive tetranectin immunostaining is seen
in developing extrinsic ocular muscles of a mouse embryo at day 12.5 of gestation, shown in larger magnification in D. A cross-section of
a developing limb with positive tetranectin immunostaining of developing muscles is shown in E and in larger magnification in F. The
following symbols are used: Arrows point to developing muscles, M is medulla oblongata, G is dorsal root ganglion, and C is cartilage. The
1B11 mAb was used at a dilution of 1:100. Sections were counterstained with hematoxylin. Scale bars are 57 mm in A, 18 mm in B, 45 mm
in C, 16 mm in D, 57 mm in E, and 25 mm in F.
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growth medium, but within 2 days after transfer into low
mitogen medium and the onset of myogenesis, tetranectin
mRNA was detected by RT-PCR (Fig. 8C). Immunostaining
with antibodies to tetranectin demonstrated an intense
cytoplasmic immunoreactivity of differentiating myoblast
and myotubes, while no cytoplasmic staining was observed
in undifferentiated myogenic cells kept in growth medium.
Interestingly, several multinucleated C2C12 cells exhibited
a distinct patchy cell surface immunostaining (Fig. 8E).
Pluripotent ES can be induced to differentiate into many
cell types in vitro, including skeletal muscle (Rohwedel et
al., 1994). Thirty days after embryoid bodies were plated on
tissue culture dishes numerous multinucleated myotubes
had developed (Fig. 9A), and these exhibited cell surface
staining with tetranectin antibodies (not shown). Further-
more, patchy immunoreactivity was found underneath the
cells (Fig. 9C), possibly associated with focal adhesions. In
addition, in some of the myofibers tetranectin immunore-
activity accumulated at the ends (Fig. 9B), a pattern that
appears to recapitulate the tetranectin immunostaining
observed at the myotendinous junctions during embryonic
development (shown in Figs. 4C and 4D).
Translational activity of tetranectin mRNA in limbs and
lung—Possible implication for function of tetranectin in
tissue and serum. During our studies on the temporal and
spatial distribution of tetranectin we noticed that in some
tissues such as the limbs, there was a correlation between
FIG. 5. Localization of tetranectin immunostaining at the myofas-
cial junction in newborn mice. Limb tissue was fixed in cold 96%
ethanol/acetic acid (99:1 v/v), embedded in paraffin, and analyzed for
the presence of tetranectin immunoreactivity using the 1B11 mAb.
Sections were counterstained with hematoxylin. Intense immuno-
staining was found at the junction of the muscle cells and the fascial,
or epimysial, connective tissue. Scale bar is 25 mm.
FIG. 6. Tetranectin expression is stimulated during muscle regeneration after injury. M. tibialis anterior was injected with Marcaine and 3 days
later tissue specimens were fixed in cold 96% ethanol/acetic acid (99:1 v/v), embedded in paraffin, and analyzed for the presence of tetranectin
immunoreactivity using the 1B11 mAb. (A) A low-magnification photograph showing a necrotic muscle fiber. Tetranectin immunostaining is
apparent at the ends of the stumps (arrows) and in some individual cells in between. Note that the surrounding normal muscle fibers do not
exhibit any tetranectin immunostaining. B and C demonstrate at a higher magnification tetranectin immunostaining in the stumps (B) and
intracellularly in the myoblasts (C). Sections were counterstained with hematoxylin. Scale bars are 30 mm in A, 14 mm in B, and 14 mm in C.
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the level of tetranectin mRNA observed by Northern blot-
ting and the amount of protein detected by immunostaining
(Figs. 1 and 4). However, despite the relatively high levels of
tetranectin mRNA in other tissues such as the lungs (Fig.
1), we were unable to detect significant tetranectin immu-
noreactivity in lung tissue either during embryogenesis or
in newborn mice (not shown). This led us to compare
translational activity of tetranectin mRNA in limbs and
lung. Polysomes from newborn limbs and lung were frac-
tionated by sucrose gradient centrifugation and the sedi-
mentation of tetranectin mRNA was determined by slot-
blot analysis (Fig. 10). Tetranectin mRNA cosedimented
with polysomes in both limbs and lung, with an average
loading of five ribosomes in the limbs and four in the lung;
this indicates that tetranectin mRNA is translated to a
similar degree in lung and limbs. Since the protein is not
tissue associated in the lung, it may be rapidly secreted into
the extracellular milieu.
DISCUSSION
The number of proteins known to affect or to be ex-
pressed in skeletal muscle cells during development and
regeneration is extensive (Hauschka, 1994; Bischoff, 1994;
Rudnicki and Jaenisch, 1995; Yun and Wold, 1996; Tajba-
khsh and Cossu, 1997). We now add to this list tetranectin.
In this report, we demonstrate a developmental regulation
of tetranectin expression with myogenesis during mouse
embryogenesis, skeletal muscle regeneration, and muscle
cell differentiation in vitro.
During mouse embryogenesis, tetranectin expression ap-
peared in the second half of gestation. Tetranectin mRNA
could be detected in mouse embryos from day 14.5 and a
strong hybridization signal continued to be present until
birth, as determined by RT-PCR and Northern blotting.
FIG. 7. Tetranectin expression is stimulated during muscle regen-
eration in dystrophic mdx mice. Hind leg muscle specimens of an
8-week-old mdx mouse were fixed in cold 96% ethanol/acetic acid
(99:1 v/v), embedded in paraffin, and analyzed for the presence of
tetranectin immunoreactivity using the 1B11 mAb. Small regener-
ating myoblasts and myotubes exhibit tetranectin immunoreactiv-
ity while the surrounding fibers do not. The section was counter-
stained with hematoxylin. Scale bar is 20 mm.
FIG. 8. Induction of tetranectin mRNA and protein during the in
vitro myogenic differentiation of C2C12 cells. (A) Phase-contrast
micrographs of mouse C2C12 myogenic cells that were cultured in
DMEM containing 10% fetal bovine serum and (B) at confluency
induced to form multinucleated myotubes by growing in medium
containing 2% horse serum. (C) RT-PCR was performed using total
RNA extracted from undifferentiated (lane 1) and from differentiating
cultures after 1, 2, 3, 5, 6, 10, and 14 days (lanes 2–8, respectively), and
the amplification products were visualized on ethidium bromide-
stained agarose gels. Tetranectin transcripts can be detected 2 days
after onset of differentiation (lane 3). (D) RT-PCR control showing the
292-bp GADPH amplification product examined in parallel, lanes
1–8. (E) Immunostaining with the mAb 1B11 to tetranectin demon-
strates a distinct cell surface staining of the myotubes. (F) Control
with normal mouse serum replacing the monoclonal antibody is
shown. Scale bars are 50 mm in A and B and 32 mm in E and F.
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Analysis of the tissue distribution of tetranectin protein
during mouse embryogenesis showed that it was present in
the developing bone (data not shown) and muscle (Figs. 3
and 4 and Table 1) and was already detected at day 12.5. At
this time of development the immunostaining intensity
was not prominent and few myoblasts were immunoreac-
tive, which explains why tetranectin mRNA was not de-
tected in total RNA extracted from whole mouse embryos.
From this time and until birth, tetranectin immunoreactiv-
ity was found in most developing muscle cells, coinciding
with differentiation and maturation of the muscle fibers.
The tetranectin immunostaining ceased after birth and no
appreciable immunostaining was found in normal adult
skeletal muscle. Thus, the presence of tetranectin is devel-
opmentally regulated during skeletal myogenesis, being
associated with myofiber formation. The association of
tetranectin with myofiber formation was also observed in
skeletal muscle regeneration after injury, in mdx mice, and
in differentiating muscle cells in vitro.
Interestingly, tetranectin appears to accumulate at ‘‘junc-
tional sites,’’ pointing to a role in cell matrix interactions in
muscle morphogenesis. Tetranectin immunostaining was
prominent at the myotendinous junctions, which are con-
sidered the striated muscle equivalent of focal adhesion
sites and contain several receptors and extracellular matrix
components, the major being the a7b1D integrin, tenascin,
and a2 and b2 chain-containing laminin isoforms (Chiquet
and Fambrough, 1984; Engvall et al., 1990; Belkin et al.,
1996). Tetranectin was also enriched at developing myofas-
cial junctions, which are structurally similar to the myo-
tendinous junctions (Ja¨rvinen et al., 1992) and lie adjacent
to the compositionally distinct epimysial ECM (Fernandez
et al., 1991). During regeneration after muscle injury, tet-
ranectin protein was seen at the stumps of the damaged
myofibers. Likewise, tetranectin immunostaining was seen
at the cell surface at apparent focal adhesion points in
differentiating C2C12 and ES cells in vitro. This is in
keeping with the possibility that tetranectin is involved in
cell–matrix interactions. Although, based on the mRNA
data, it is reasonable to assume that the tetranectin ob-
served in the differentiating muscle cells is produced by the
muscle cells, we cannot exclude that some may also derive
from serum.
Tetranectin is present both in serum (15 6 2 mg/liter) and
ECM. However, the cellular source of serum tetranectin has
not been determined. Many serum proteins are produced in
the liver, but little or no tetranectin mRNA is detected in
this tissue (Fig. 1; Wewer and Albrechtsen, 1992; Berglund
and Petersen, 1992; Ibaraki et al., 1995; Sørensen et al.,
1995) suggesting that the liver is not a major source. Other
organs, including the lung, have an apparently high level of
tetranectin mRNA without any distinct tissue localization
detectable by immunostaining. The polysomal distribution
of tetranectin mRNA in newborn mouse lung and limbs
showed that it was equally well translated in both tissues.
These results indicate that in some tissue, such as develop-
ing limbs, tetranectin may function locally, whereas in
other tissues, such as the lung, tetranectin production may
be destined for the circulation.
What is the function of tetranectin in serum and ECM
during such processes as myogenesis, osteogenesis, fibrino-
lysis, and carcinogenesis? Tetranectin shows some similari-
ties to the matricellular proteins SPARC, thrombospondin,
and tenascin, which have diverse functions and are impli-
cated in development and in pathological conditions. Ma-
tricellular proteins were defined as proteins that are not
primarily structural ECM components, but which perform
their functions by interacting with other ECM proteins, cell
surface receptors, cytokines, and proteases (Sage and Born-
stein, 1991; Bornstein, 1995). The ability of tetranectin to
bind sulfated polysaccharides (Clemmensen, 1989) suggests
that it may interact with the glycosaminoglycan chains of
proteoglycans present at the cell surface or in the ECM.
Tetranectin binds to plasminogen, as do SPARC and thro-
mobospondin, indicating that it may have a role in regulat-
ing pericellular proteolysis, by influencing the rate of plas-
FIG. 9. Myogenic differentiation of ES cells is accompanied by the
appearance of tetranectin immunostaining. The mouse ES cells
were allowed to differentiate as described under Materials and
Methods. The cultures were examined 30 days after plating the
embryoid bodies on gelatin-coated dishes. (A) A multinucleated
myotube immunoreactive with antiserum to skeletal myosin is
seen. (B) Tetranectin immunostaining accumulates at the ends of
myotubes. (C) Tetranectin immunostaining is located at the bot-
tom surface of the myotube cell. mAb 1B11 was used. The
surrounding nonmuscle cells do not show any immunoreactivity.
Scale bars are 1.1 mm in A and 2.2 mm in B and C.
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minogen activation or its localization to the ECM or cell
surfaces. In addition to hydrolysis of fibrin clots and ECM
proteins, plasmin is implicated in the proteolytic activation
of the latent forms of metalloproteases and growth factors
and in the release of growth factors stored in the ECM.
Tetranectin may thus be regulating cell proliferation or
ECM remodeling that occurs during the development of
bone and muscle. As tetranectin is present in the tumor
stroma (Christensen and Clemmensen, 1991; Wewer and
Albrechtsen, 1992; Høgdall et al., 1993; DeVries et al.,
1996), which is believed to reflect an aberrant wound-
healing process, this implies a possible role for tetranectin
during normal wound healing. Tetranectin stimulates the
migration of monocytes in vitro (Nielsen et al., 1993),
indicating that it may influence cell adhesion by interac-
tion with cell surface receptors or ECM proteins. Another
type of lectin, L14/galectin-1, modulates the binding of
laminin to the a7b1 integrin receptor (Gu et al., 1994), and
FIG. 10. Polysomal distribution of tetranectin mRNA in lung and limbs. Top panel shows the sedimentation profiles of the
detergent-solubilized lysates from newborn mouse lungs and limbs in a 20–47% sucrose gradient in the presence of 5 mM MgCl2, as
measured by the absorbance at 260 nm. A comparison of the A260 sedimentation profiles from lungs and limbs showed that only a minor
fraction of the ribosomes are associated with polysomes in the lungs, whereas about 60% of the ribosomes are associated with polysomes
in the limbs. Middle panel shows the slot-blot analysis of RNA from 1-ml fractions of the gradient after hybridization with a tetranectin
cDNA probe. Bottom panel shows the quantitative analysis of the slot-blot hybridization signals, expressed as photon-stimulated
luminescence (PSL). Tetranectin mRNA was associated with polysomes in both lung and limbs. After release of the ribosomal subunits by
addition of 10 mM EDTA to the gradients (data not shown), tetranectin mRNA shifted to the top of the gradient and sedimented as 40–60S
ribonucleoprotein particles.
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the C-type lectin domains of lecticans (aggrecan, brevican,
neurocan, and versican) have been demonstrated to interact
with the adhesion protein tenascin-R by protein–protein
interactions (Aspberg et al., 1997). Based on these consider-
ations we propose that tetranectin be classified as a matri-
cellular protein together with SPARC, thrombospondin,
and tenascin. Studies in progress address the specific inter-
actions of tetranectin with cells, ECM proteins, and pro-
teases and its role in the biological processes.
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